ClinicalTrials.gg
RecruitingNCT06046586IN-FACT-1Updated Sep 9, 2026

Internet-Delivered Psychological Treatment for Cancer Survivors

An interventional study of Support and information and Behavioral activation in Cancer Survivors, Anxiety and Depression, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Depression by Karolinska Institutet — 8 open to participants now, 11 under way, none of them phase 3. Depression · Karolinska Institutet.

Planned enrollment
6th of 34
400 · median 130
Started
2025
with 4 others
No phase
31 of 42
5 open now
Primary completion
2029-12
later than 10 of 10 live
Registered
30th of 42
by date

Among the 42 studies in Depression by Karolinska Institutet, this one is the 6th largest by planned enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2025, is one of 31 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 30th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

8 of the 42 studies in Depression by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Depression by Karolinska Institutet, or all of them as a file.
02

Study summary

Negative psychological effects of cancer are common, but cancer survivors are rarely offered structured psychological treatment. Internet-delivered treatments have shown some promise, but specific treatment components have not been empirically evaluated which means that it is not clear which therapies that should be prioritized. In this randomized factorial trial at Karolinska Institutet, Stockholm, Sweden, 400 cancer survivors with psychiatric symptoms are enrolled in variations on a 10-week therapist-guided online psychological treatment intended to address the negative psychological long-term effects of cancer. The aim is to determine the contribution of treatment components to the overall effect.

03

Conditions studied

  • Cancer Survivors
  • Anxiety
  • Depression

Browse trials for

Keywords

  • psycho-oncology
  • randomized factorial trial
  • Internet-delivered cognitive behavior therapy
04

In context

Depression Reclassified

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 400 is above the median of 81 across 7,089 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cancer survivor at least 0.5 years after main therapy
  • anxiety or depression (Patient Health Questionnaire 9 [PHQ-9]≥10, or Generalized Anxiety Disorder 7 [GAD-7]≥8, or 9-item Fear of Cancer Recurrence Inventory [FCRI-9]≥16)
  • At least 18 years old
  • Resident of Region Stockholms, Västra Götalandsregionen, or Region Skåne, Sweden (listed and de facto)
  • Sufficient technical knowledge and knowledge of the Swedish language to take part in a text-based online treatment
  • Continuous access to an electronic device that can be used to access the study web platform

Exclusion criteria

Exclusion Criteria:

  • Recurrent thoughts of suicide, as based on clinical judgement aided by the structured interview and the self-report version of the Montgomery-Åsberg Depression Rating Scale (MADRS-S) item 9
  • Severe medical condition (e.g., very poor prognosis, stage IV cancer), severe psychiatric disorder (e.g., psychotic disorder, bipolar disorder, or severely debilitating substance use disorder, severe depression), or medical treatment (e.g., chemotherapy, immunotherapy, radiotherapy) that makes the treatment unfeasible
  • Other ongoing psychological treatment
  • Continuous psychotropic medication not stable for the past 4 weeks, or not expected to remain stable during the treatment period
  • Planned absence for more than one week of the intended treatment period
  • No complete the pre-treatment assessment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Participant)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Internet-delivered psychological treatment, arm #1

    Support and information + Behavioral activation

    Behavioral: Support and information · Behavioral: Behavioral activation

  • Experimental
    Internet-delivered psychological treatment, arm #2

    Support and information + Systematic exposure with mindfulness training

    Behavioral: Support and information · Behavioral: Systematic exposure with mindfulness training

  • Experimental
    Internet-delivered psychological treatment, arm #3

    Support and information + Promotion of health behaviors

    Behavioral: Support and information · Behavioral: Promotion of health behaviors

  • Experimental
    Internet-delivered psychological treatment, arm #4

    Support and information + Behavioral activation + Systematic exposure with mindfulness training

    Behavioral: Support and information · Behavioral: Behavioral activation · Behavioral: Systematic exposure with mindfulness training

  • Experimental
    Internet-delivered psychological treatment, arm #5

    Support and information + Behavioral activation + Promotion of health behaviors

    Behavioral: Support and information · Behavioral: Behavioral activation · Behavioral: Promotion of health behaviors

  • Experimental
    Internet-delivered psychological treatment, arm #6

    Support and information + Systematic exposure with mindfulness training + Promotion of health behaviors

    Behavioral: Support and information · Behavioral: Systematic exposure with mindfulness training · Behavioral: Promotion of health behaviors

  • Experimental
    Internet-delivered psychological treatment, arm #7

    Support and information + Behavioral activation + Systematic exposure with mindfulness training + Promotion of health behaviors

    Behavioral: Support and information · Behavioral: Behavioral activation · Behavioral: Systematic exposure with mindfulness training · Behavioral: Promotion of health behaviors

  • Experimental
    Internet-delivered psychological treatment, arm #8

    Support and information

    Behavioral: Support and information

Interventions

  • BehavioralSupport and information

    Emotional and technical support. Information about the long-term effects of cancer.

  • BehavioralBehavioral activation

    Behavioral activation with existential themes and emphasis on values and relationships.

  • BehavioralSystematic exposure with mindfulness training

    Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.

  • BehavioralPromotion of health behaviors

    An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.

07

What researchers measure

Primary outcomes

  1. General anxiety

    General Anxiety Disorder 7 (GAD-7, theoretical range: 0-21, where a higher score indicates more general anxiety). The phrasing is revised to concern the past week. The conventional version is also administered at screening (within 6 months before treatment), used to inform the eligibility assessment and to describe the sample.

    Time frame: Pre-treatment (within 2 weeks before treatment), via weekly assessments, to post-treatment (after treatment, completed within 90 days). Secondary analysis: from pre-treatment up to follow-up 12-months after treatment (completed within 90 days).

  2. Depressive symptoms

    Patient Health Questionnaire 9 (PHQ-9, theoretical range: 0-27, where a higher score indicates more symptoms of depression). The phrasing is revised to concern the past week. The conventional version is also administered at screening (within 6 months before treatment), used to inform the eligibility assessment and to describe the sample.

    Time frame: Pre-treatment (within 2 weeks before treatment), via weekly assessments, to post-treatment (after treatment, completed within 90 days). Secondary analysis: from pre-treatment up to follow-up 12-months after treatment (completed within 90 days).

  3. Fear of cancer recurrence

    9-item Fear of Cancer Recurrence Inventory (FCRI-9, theoretical range: 0-36, where a higher score indicates a more pronounced fear of cancer recurrence). This scale is also administered at screening (within 6 months before treatment), used to inform the eligibility assessment and to describe the sample.

    Time frame: Pre-treatment (within 2 weeks before treatment), via weekly assessments, to post-treatment (after treatment, completed within 90 days). Secondary analysis: from pre-treatment up to follow-up 12-months after treatment (completed within 90 days).

Secondary outcomes

  1. Health anxiety

    14-item Health Anxiety Inventory (HAI-14, theoretical range: 0-42, where a higher score indicates more health anxiety). This scale is also administered at screening (within 6 months before treatment), used to inform the eligibility assessment and to describe the sample.

    Time frame: Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 90 days). Secondary analysis: from pre-treatment up to follow-up 12-months after treatment (completed within 90 days).

  2. Somatic symptom burden

    Somatic Symptom Scale 8 (SSS-8, theoretical range: 0-32, where a higher score indicates a higher somatic symptom burden). Exploratory secondary analyses will be based on individual items, each scored 0-4. This scale is also administered at screening (within 6 months before treatment), used to inform the eligibility assessment and to describe the sample.

    Time frame: Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 90 days). Secondary analysis: from pre-treatment up to follow-up 12-months after treatment (completed within 90 days).

  3. Body image distress

    Body Image Scale (BIS, theoretical range: 0-30, where a higher score indicates a higher level of body image distress)

    Time frame: Screening (within 6 months before treatment) to post-treatment assessment (immediately after treatment, completed within 90 days)

  4. Disability

    12-item World Health Organization Disability Assessment Schedule 2.0 (WD2-12, theoretical range: 0-100, where a higher score indicates more disability). This scale is also administered at screening (within 6 months before treatment), used to inform the eligibility assessment and to describe the sample.

    Time frame: Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 90 days). Secondary analysis: from pre-treatment up to follow-up 12-months after treatment (completed within 90 days).

  5. Treatment credibility and patient expectancy of improvement

    Credibility/Expectancy scale (C/E scale, theoretical range: 0-50, where a higher score indicates higher credibility/expectancy)

    Time frame: Week 2 of treatment

  6. Relationship with the therapist (therapeutic alliance)

    Working Alliance Inventory (WAI, theoretical range: 6-42, where a higher score indicates a stronger therapeutic alliance)

    Time frame: Week 2 of treatment

  7. Patient satisfaction with treatment

    8-item Client satisfaction questionnaire (CSQ-8, theoretical range: 8-32, where a higher score indicates higher satisfaction with treatment)

    Time frame: Post-treatment assessment (immediately after treatment, completed within 90 days)

  8. Adverse events

    Brief questionnaire with three free-text items, each of which can be used to report an adverse event. For each adverse event, a rating is given of initial negative impact, and negative impact at post-treatment, on a scale from 0: "not at all", to 3: "very negatively". Reported primarily in terms of the number of participants reporting at least one adverse event.

    Time frame: Post-treatment assessment (immediately after treatment, completed within 90 days)

  9. Perceived negative effects of treatment

    20-item Negative Effects Questionnaire (NEQ-20). This will be reported as the proportion of endorsed items in the following subdomains: increase in symptoms, perceived insufficient quality of treatment, dependency, stigma, and hopelessness.

    Time frame: Post-treatment assessment (immediately after treatment, completed within 90 days)

  10. Lifestyle behaviors

    Lifestyle Behaviors Questionnaire (LBQ). The LBQ comprises 11 items that cover tobacco use, alcohol use, physical activity and diet. Dichotomous risky lifestyle behavior variables will be derived from the LBQ in terms of: "At least one unhealthy lifestyle behavior", "Daily smoking", "Binge drinking more than once a month OR more than 9/14 (w/m) glasses/week", "Insufficient physical activity, less than 150 minutes/week", and "Notably unhealthy dietary habits (diet index 0-4)". Risky lifestyle behavior will be defined as daily smoking, binge drinking of 4/5 (women/men) drinks at one occasion more than once a month and/or more than 9/14 (women/men) standard glasses of alcohol weekly, insufficient physical activity (\<150 minutes/week) or significantly unhealthy diet habits (a score of 0-4 on a diet index in the questionnaire, ranging from 0-12).

    Time frame: Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 90 days).

Other outcomes

  1. Process and target variables: Behavioral activation

    3-item Behavioral Activation for Depression Scale - ACtivation subscale (BADS-AC-3, theoretical range: 0-18, where a higher score indicates a higher level of behavioral activation). This scale is also administered at screening (within 6 months before treatment), used to inform the eligibility assessment and to describe the sample.

    Time frame: Pre-treatment (within 2 weeks before treatment), once each week during treatment (9 assessments in total), post-treatment (after treatment, completed within 90 days), and at follow-up 6 and 12 months after treatment (each completed within 90 days).

  2. Process and target variables: Symptom preoccupation

    Symptom Preoccupation Scale (preliminary scale). A higher score indicates higher degree of preoccupation with symptoms. This is to be regarded as an an item pool, and the scale is is under development, which means that the total range cannot be preregistered.

    Time frame: Pre-treatment (within 2 weeks before treatment), once each week during treatment (9 assessments in total), post-treatment (after treatment, completed within 90 days), and at follow-up 6 and 12 months after treatment (each completed within 90 days).

  3. Process and target variables: Physical activity

    Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ, theoretical range 0-99, where a higher score indicates a higher level of physical activity). If necessary for statistical modeling, the GSLTPAQ will be dichotomized to indicate active (≥24) vs. insufficiently active (\<24).

    Time frame: Pre-treatment (within 2 weeks before treatment), once each week during treatment (9 assessments in total), post-treatment (after treatment, completed within 90 days), and at follow-up 6 and 12 months after treatment (each completed within 90 days).

  4. Process and target variables: Health-related self-efficacy

    Based loosely on the Arthritis Self-efficacy Scale. Theoretical range of 0-60, where a higher score indicates a higher level of general health-related self-efficacy.

    Time frame: Pre-treatment (within 2 weeks before treatment), once each week during treatment (9 assessments in total), post-treatment (after treatment, completed within 90 days), and at follow-up 6 and 12 months after treatment (each completed within 90 days).

  5. Basis for cost-effectiveness analysis: Utility (health-related quality of life)

    EuroQol 5D (EQ-5D). Theoretical range: 0-1, i.e., scored as utility for the purpose of calculating quality-adjusted life years for health economic analysis. A higher utility score indicates a higher health-related quality of life.

    Time frame: Pre-treatment assessment (within 2 weeks before treatment), post-treatment assessment (immediately after treatment, completed within 90 days), 6 months after treatment (completed within 90 days), 12 months after treatment (completed within 90 days).

  6. Basis for cost-effectiveness analysis: Resource use (medical costs and productivity losses)

    Trimbos Institute and Institute of Medical Technology Questionnaire for Costs Associated with Psychiatric Illness (TIC-P). This instrument is scored in terms of resource use for the purpose of calculating societal costs for health economic analysis.

    Time frame: Pre-treatment assessment (within 2 weeks before treatment), post-treatment assessment (immediately after treatment, completed within 90 days), 6 months after treatment (completed within 90 days), 12 months after treatment (completed within 90 days).

  7. Process and target variables: Health anxiety behaviors

    Health Anxiety Behavior Inventory (HABI, scored as four subscales of "bodily preoccupation and checking", "information- and reassurance-seeking", "prevention and planning" and "overt avoidance"; each with a theoretical range of 0-9 where a higher score indicates a higher level of health anxiety behaviors within each respective subdomain)

    Time frame: Pre-treatment (within 2 weeks before treatment), once each week during treatment (9 assessments in total), post-treatment (after treatment, completed within 90 days)

  8. Screening only: Alcohol use

    Alcohol Use Disorders Identification Test (AUDIT, theoretical range: 0-40, where a higher score indicates more problematic alcohol use). This scale is administered to inform the eligibility assessment and describe the sample only.

    Time frame: Screening (within 6 months before treatment)

  9. Screening only: Substance use

    Drug Use Disorders Identification Test (DUDIT, theoretical range: 0-44, where a higher score indicates more problematic substance use). This scale is administered to inform the eligibility assessment and describe the sample only.

    Time frame: Screening (within 6 months before treatment)

08

Study locations

1 of 1 sites recruiting
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data from this pilot study fall under Swedish and European Union data protection and privacy legislation and can therefore not be share in their entirety. Reasonable requests may be directed to the corresponding author, and will be considered on a case-by-case basis.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2029, 56 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 56 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Sep 21, 2023
StartActual
Apr 10, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2031
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06046586
Collaborators
Region Stockholm
Responsible party
Erland Axelsson (Principal Investigator, Karolinska Institutet) — Principal investigator
First posted
Sep 21, 2023
Start date
Apr 10, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Sep 9, 2026

Study contacts

Erland Axelsson, PhD
Contact
erland.axelsson@ki.se
0706171039 ext. +46
Erland Axelsson, PhD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion